Related Compounds
Compounds connected by the same goals, effects, or research topics.
Herb Profile
Mucuna
Mucuna pruriens
Mucuna (Mucuna pruriens) carries a Grade C rating — limited evidence.
Last reviewed: •3 sources citedReport a correctionProfile-wide ·C Limited
Use extra caution — Can cause levodopa like adverse effects; caution with Parkinson's drugs, MAO inhibitors, psychosis, pregnancy, and cardiovascular disease. Details
- Evidence
- Limited Evidence
- Typical onset
- Varies by prep
- Safety rating
- Moderate caution
- Best for
- Dopamine Support, Neuroprotective, Libido, Stress
- Avoid / review if
- Psychosis/Bipolar Risk, Melanoma History Caution, Pregnancy/Breastfeeding
At a glance
From this profile's structured data- Evidence
- Grade C
- Safety
- Can cause levodopa-like adverse effects; caution with Parkinson's drugs, MAO inhibitors, psychosis, pregnancy, and cardiovascular disease.
- Profile context
- dopamine_support, neuroprotective, libido
Next stepsWhere to go next — guides & comparisons
Continue reading
- If you want help with anxiety or stress → Anxiety & stress guides
- If you want to browse more herbs → All herbs
Safety
Safety & Cautions
Can cause levodopa like adverse effects; caution with Parkinson's drugs, MAO inhibitors, psychosis, pregnancy, and cardiovascular disease.
Elevated caution
Caution level: Elevated. One caution category applies — read it before use.
- Pregnancy/Breastfeeding CautionPregnancy or breastfeeding caution language is present.
Detailed safety fields
Pregnancy, breastfeeding, and contraindications
- Psychosis/Bipolar Risk
- Melanoma History Caution
- Pregnancy/Breastfeeding
- Use With Levodopa Drugs Without Clinician Supervision
- May Interact With Levodopa/Carbidopa
- MAOIs
- Antipsychotics
- Antihypertensives
- And Dopaminergic Drugs.
Safety classifications
- Pregnancy/Breastfeeding Caution: Pregnancy or breastfeeding caution language is present.
Full safety note
- Can cause levodopa like adverse effects; caution with Parkinson's drugs, MAO inhibitors, psychosis, pregnancy, and cardiovascular disease.
Safety labels
- Pregnancy/Breastfeeding Caution
Evidence-based safety
Caution when combined
Severity and certainty are shown separately. A high-priority caution can still be theoretical: these pairings are screened from shared contraindication mechanisms and are not automatically documented clinical interactions. Provenance identifies the source fields that produced each flag; it does not upgrade the certainty of the pairwise claim.
High-Priority Caution
26 flagged pairingsSerotonergic activity
High-Priority Caution
26 flagged pairingsSerotonergic activity
Representative pairings are shown below. Large mechanism groups are intentionally summarized to keep profiles focused and crawl-efficient.
Serotonergic activityCertainty: Theoretical
Data provenance recorded for 26 of 26 pairings in this mechanism group.
- 5-HTP — Theoretical interaction certainty
- Caffeine — Theoretical interaction certainty
- crocetin — Theoretical interaction certainty
- crocin — Theoretical interaction certainty
- Crocus Sativus — Theoretical interaction certainty
- Damiana — Theoretical interaction certainty
- DMT — Theoretical interaction certainty
- Ginkgo — Theoretical interaction certainty
- Panax Red Ginseng — Theoretical interaction certainty
- Panax White Ginseng — Theoretical interaction certainty
- Harmaline — Theoretical interaction certainty
- Harmine — Theoretical interaction certainty
+14 more pairings share this mechanism. Use the Safety Checker to review a specific combination.
Moderate Caution
81 flagged pairingsBlood-pressure effects
Moderate Caution
81 flagged pairingsBlood-pressure effects
Representative pairings are shown below. Large mechanism groups are intentionally summarized to keep profiles focused and crawl-efficient.
Blood-pressure effectsCertainty: Theoretical
Data provenance recorded for 81 of 81 pairings in this mechanism group.
- Agmatine sulfate — Theoretical interaction certainty
- ajoene — Theoretical interaction certainty
- Allicin — Theoretical interaction certainty
- American Ginseng Extract — Theoretical interaction certainty
- Andrographis — Theoretical interaction certainty
- Angelica Dahurica — Theoretical interaction certainty
- Astaxanthin — Theoretical interaction certainty
- Astragalus Membranaceus — Theoretical interaction certainty
- Beetroot extract — Theoretical interaction certainty
- Berberis — Theoretical interaction certainty
- Bicarbonate — Theoretical interaction certainty
- Black Seed — Theoretical interaction certainty
+69 more pairings share this mechanism. Use the Safety Checker to review a specific combination.
Evidence
Evidence Summary
Evidence lens
Read as directional context, not settled clinical proof.
LimitedLimited Evidence
Human clinical evidence: Present in source signals
Mechanistic / preclinical: Mechanism mapped — Oxidative Stress Modulation · Mitochondrial Support · Neurotransmitter Modulation
Research maturity: Emerging research — Long Term Human Evidence May Be Limited.
Safety boundary: Safety note available — Can cause levodopa like adverse effects; caution with Parkinson's drugs, MAO inhibitors, psychosis, pregnancy, and cardiovascular disease.
This profile cites 3 human studies.
Study design details
Evidence Grade
Grade C: Limited Evidence
Evaluation of methodological rigor, population reach, and evidence alignment.
- Design Match
- Systematic review
- Risk of Bias
- Low
- Consistency
- Consistent
Strongest recorded design is a systematic review, drawn from 6 recorded studies, 3 in people. No disagreement is recorded across them.
How evidence grades work
Each grade reflects the strength and consistency of published human evidence — not marketing claims. Grades are based on study count, design quality, effect size, consistency, and recency.
- Strong
- Multiple RCTs, consistent direction, adequate effect size
- Moderate
- Some RCTs or consistent observational data in humans
- Preliminary / Mixed
- Animal or in-vitro only, or conflicting human data
- Traditional / Theoretical
- Traditional use only; no controlled human trials
Clinical Study Summaries (6)2 human evidence sources · 0 human trials · Participant totals not consistently reported · Consistency not yet classifiable
Filter by study class
Showing 6 of 6 studies.
What the evidence actually shows
This table contains 6 structured sources, including 2 human evidence sources; 0 are human trials.
| Study | Design | N | Dose | Duration | Population | Outcome | Result & magnitude | Source |
|---|---|---|---|---|---|---|---|---|
Aktaş E et al. · CNS Neurosci Ther · 2025 Background | Systematic review Uses a predefined method to find and evaluate relevant studies, but may or may not pool their results statistically. | — | — | — | — | — | — | PubMed → |
Background | Systematic review Uses a predefined method to find and evaluate relevant studies, but may or may not pool their results statistically. | — | — | — | — | — | A 2025 systematic review found only 5 clinical trials totaling 108 participants. Results were generally favorable for motor symptoms/on-time and some therapy complications, but only one trial was rated high quality and interventions were heterogeneous. The evidence remains promising rather than definitive. | PubMed → |
Handwerker HO et al. · Neurosci Lett · 2010 Background | Narrative review Summarizes selected literature without the full prespecified search and selection methods of a systematic review. | — | — | — | — | — | — | PubMed → |
Soares AR et al. · Plant Signal Behav · 2014 Background | Narrative review Summarizes selected literature without the full prespecified search and selection methods of a systematic review. | — | — | — | — | — | — | PubMed → |
Background | Other / unclear The study design is not yet classified clearly enough to infer its place in the evidence hierarchy. | — | — | — | — | — | A 2026 phase-2 study (32 participants) found similar clinical outcomes to levodopa plus a decarboxylase inhibitor over 12 months, but adverse events were more frequent with Mucuna and some participants discontinued. Evidence remains small and specialist-context only. | PubMed → |
Background | Other / unclear The study design is not yet classified clearly enough to infer its place in the evidence hierarchy. | — | — | — | — | — | A 16-week crossover pilot in Parkinson disease had substantial discontinuation with Mucuna because of gastrointestinal and motor adverse effects, highlighting tolerability variability. | PubMed → |
Dosing & Timing
- No standardized dose
- Preparation specific; use standardized product label for Seed powder/extract standardized to L DOPA and require source backed dosage review before therapeutic claims.
How Mucuna works
Simplified mechanism pathway based on preclinical and pharmacological evidence. Does not confirm clinical efficacy.
Mechanism Pathway — How Mucuna Works
CompoundTarget / ReceptorMechanismEffect / Outcome
Mechanisms & biological pathways (preclinical)
- Oxidative Stress Modulation
- Mitochondrial Support
- Neurotransmitter Modulation
- Stress Response Modulation
Compare related active botanicals
Explore botanicals with similar chemistry, effects, or safety considerations in the Botanical Activity Atlas.
Guides that use Mucuna
Compare & Sourcing
Compare side-by-side tradeoffs or verify active marker guidelines.
Sourcing options
Mucuna Pruriens product picks
Recommendation status
Product recommendations are not shown for this profile because the current site safety and monetization policy does not permit them.
Product form & quality guidelines
When sourcing Mucuna, verify the label for:
- Standardized extract: Confirm active content percentages on the supplement facts panel (e.g. standardized to specific marker compounds) rather than simple raw herb weights.
- Third-party testing: Look for independent purity labels (USP, NSF, ConsumerLab, or Eurofins) to ensure the product is free from heavy metals, solvents, and contaminants.
- Form bioavailability: Ensure the form matches evidence-supported configurations (e.g. standardized active extracts like bacosides, withanolides, or curcuminoids) for optimal onset and digestion tolerance.
Safety first · Harm reduction
This information is educational and not medical advice. Start low, avoid risky combinations, and consult a licensed clinician before making health decisions—especially if you use medications, have diagnosed conditions, or are pregnant/breastfeeding.
Learn how we evaluate confidence, safety, and intensity on the methodology page.
Editorial Review
Checked against primary sources, cited evidence, and contraindication language before publication. Evidence claims, safety language, and affiliate modules are reviewed independently. Not personal medical advice.
Help improve this profile
Was this useful for your research?
These controls record only the page and the structured choice you make when analytics consent is enabled. Please don’t include personal medical information in research requests.
Was this evidence summary clear?
Did you find what you were researching?
Free safety checklist
Get the Mucuna research notes
Evidence summaries, dosing context, and safety updates for this herb — straight to your inbox.
We use your email to send the checklist and occasional evidence-first supplement updates. Unsubscribe anytime. Privacy policy.